LIBERTY Randomized Withdrawal Study: Relugolix Combination Therapy for Heavy Menstrual Bleeding Associated With Uterine Fibroids

In the pivotal LIBERTY 1 and 2 trials and long-term extension (LTE) study, once-daily relugolix combination therapy (relugolix CT: relugolix 40 mg, estradiol 1 mg, norethindrone acetate 0.5 mg) reduced menstrual blood loss (MBL) volume and pain in women with uterine fibroids (UF). Relugolix CT was well tolerated, with preservation of bone mineral density (BMD) through 52 weeks.

Source: American Journal of Obstetrics and Gynecology - September 2, 2023 Category: OBGYN Authors: Ayman AL-HENDY, Roberta VENTURELLA, Juan Camilo ARJONA FERREIRA, Yulan Li, Graziella SOULBAN, Rachel B. WAGMAN, Andrea S. LUKES Tags: Original Research: Gynecology Source Type: research